

1 State of Arkansas  
2 90th General Assembly  
3 Regular Session, 2015

HR 1044

4  
5 By: Representative E. Armstrong

6  
7 **HOUSE RESOLUTION**

8 TO SUPPORT INCREASING DIVERSITY IN CLINICAL TRIAL  
9 PARTICIPATION.

10  
11  
12 **Subtitle**

13 TO SUPPORT INCREASING DIVERSITY IN  
14 CLINICAL TRIAL PARTICIPATION.

15  
16  
17 WHEREAS, developing new medicines and other treatment options is a  
18 complex process that involves clinical trials to explore whether a medical  
19 strategy, treatment, or device is safe and effective for humans; and

20  
21 WHEREAS, volunteer participation is necessary to evaluate potential  
22 therapies for safety and effectiveness in clinical studies; and

23  
24 WHEREAS, often the enrolled patient population is not representative of  
25 United States demographics or subpopulations impacted by a particular  
26 disease; and

27  
28 WHEREAS, groups such as African-Americans and Hispanics are  
29 significantly underrepresented in clinical trials, with African-Americans  
30 representing 12% of the United States population but only 5% of clinical  
31 trial participants, and Hispanics comprising 16% of the population but only  
32 1% of clinical trial participants, according to a 2011 study by the United  
33 States Food and Drug Administration; and

34  
35 WHEREAS, despite a Congressional mandate that research financed by the  
36 National Institutes of Health include minorities, nonwhites comprise fewer



1 than 5% of participants in National Institutes of Health supported studies;  
2 and

3  
4 WHEREAS, certain medical conditions have been known to affect  
5 particular demographic groups more than others, including Type II diabetes  
6 for which African-Americans and Hispanics are twice as likely to be diagnosed  
7 on average; and

8  
9 WHEREAS, according to the Centers for Disease Control and Prevention,  
10 the sickle cell trait is common among African-Americans and occurs in about 1  
11 in 12, and sickle cell disease occurs in about 1 out of every 500 African  
12 American births compared to about 1 out of every 36,000 Hispanic births; and

13  
14 WHEREAS, race and ethnicity have also been demonstrated to affect the  
15 efficacy of a response to certain drugs, such as anti-hypertensive therapies  
16 in the treatment of hypertension in African-Americans and anti-depressants in  
17 Hispanics; and

18  
19 WHEREAS, many barriers exist that account for the low rate of  
20 participation among minority communities, including patient fear of  
21 experimentation and lack of understanding or education with regard to the  
22 importance of clinical trials in creating new treatments and cures,

23  
24 NOW THEREFORE,

25 BE IT RESOLVED BY THE HOUSE OF REPRESENTATIVES OF THE NINETIETH GENERAL  
26 ASSEMBLY OF THE STATE OF ARKANSAS:

27  
28 THAT the House of Representatives of the Ninetieth General Assembly  
29 supports ensuring that diverse populations of different racial and ethnic  
30 backgrounds are represented in clinical research, as this is an important  
31 issue that warrants the dedication of additional community resources to  
32 increase awareness on the importance of participating in clinical trials,  
33 provide support for patient participation, and promote effective partnerships  
34 with the community to achieve solutions.

35  
36 BE IT FURTHER RESOLVED THAT upon its adoption, a copy of this

1 resolution be transmitted to the President of the United States, the Vice  
2 President of the United States, members of the United States House of  
3 Representatives and the United States Senate, and other federal and state  
4 government officials as appropriate.

5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36